IB Acquisition Corp. entered into a Business Combination Agreement with GNQ Insilico Inc. in March 2026 to take GNQ public via a business combination. GNQ announced a strategic partnership with a Fortune 100 technology company to advance AI-driven drug discovery solutions.

• On March 16, 2026, IB Acquisition Corp. entered into a Business Combination Agreement with GNQ Insilico Inc., a Canadian AI-driven drug discovery company, to take GNQ public through a business combination [N1].
• GNQ Insilico Inc. announced a joint marketing and development agreement with a Fortune 100 global technology company to advance AI-powered drug discovery and precision medicine solutions, with a global territory and initial two-year term [N1].
• Significant redemptions by stockholders reduced the Trust Account funds by approximately $7.9 million, leaving about $8.2 million as of June 30, 2026, which may impact the ability to satisfy closing conditions for the business combination [S2].

The company’s management team has significant experience and networks across multiple regions and industries, which may facilitate sourcing attractive acquisition targets. The announced business combination with GNQ Insilico Inc., an AI-driven drug discovery company with a strategic partnership with a Fortune 100 technology firm, could provide a platform for growth in the healthcare technology sector. The public listing and capital access through the SPAC structure may support GNQ’s growth initiatives and market presence.

The company faces risks related to the completion of its initial business combination, including satisfying closing conditions such as stockholder approvals, court orders, and minimum net tangible assets. Significant redemptions have reduced available funds, potentially complicating the closing process and reducing liquidation value if the combination is not consummated. Conflicts of interest among management and directors due to founder shares and other obligations may affect decision-making. The SPAC structure’s inherent limitations, including limited operating history and financial resources, may deter some target companies. GNQ Insilico Inc. has limited operating history and faces risks related to executing its business plan and achieving profitability.

As a blank check company, IB Acquisition Corp. does not have an operating business moat. Its competitive advantage lies in the experience and networks of its management team and board, which are leveraged to source and evaluate potential acquisition targets. The company’s status as a public entity provides a platform for target companies to access public capital markets more efficiently than through traditional IPOs. However, the inherent limitations of a SPAC structure, including limited financial resources and the need for stockholder approvals, may constrain its competitive positioning relative to more established public companies or private acquirers.

• Completion of Business Combination: The business combination with GNQ Insilico Inc. is subject to multiple conditions including stockholder and court approvals, registration statement effectiveness, Nasdaq listing, and maintaining minimum net tangible assets. Failure to satisfy these conditions by the extended deadline may require liquidation of the Trust Account.
• Liquidity Constraints: Significant redemptions have reduced the Trust Account funds to approximately $8.2 million as of June 30, 2026, which may impair the company’s ability to meet closing conditions and reduce the per-share liquidation value if the business combination is not completed.
• Conflicts of Interest: Management and directors hold founder shares acquired at low cost and may have conflicts of interest that could influence the selection and terms of the business combination target.
• Target Company Risks: GNQ Insilico Inc. has limited operating history and faces risks related to executing its business plan, managing growth, achieving profitability, and protecting intellectual property.

• IB Acquisition Corp. is a blank check company (SPAC) formed in 2020 and converted to a Nevada corporation in 2023 [S1].
• The company’s purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, referred to as the initial business combination [S1].
• Management targets companies with enterprise value of at least $500 million, focusing on sectors including consumer goods, sports and entertainment, healthcare technology, fintech, and life sciences [S1].
• The management team and board have experience in private investing, corporate finance, restructuring, and executive management, with networks across North America, Europe, and Asia [S1].
• As of June 30, 2026, the company had cash and equivalents of $30.161 million and current assets of $256.535 million, with current liabilities of $1.839 billion as of March 31, 2026, resulting in a current ratio of 0.14 and cash ratio of 0.02 [S2].
• The company reported a net loss of $567,166 for the quarter ended June 30, 2026 [S2].
• IB Acquisition Corp. has not selected any specific business combination target prior to March 2026 but entered into a Business Combination Agreement (BCA) with GNQ Insilico Inc. on March 16, 2026 [S1][S2].
• The business combination with GNQ Insilico Inc. is subject to conditions including stockholder approvals, court approval, registration statement effectiveness, Nasdaq listing, and minimum net tangible assets of $5 million after redemptions and PIPE investments [S2].
• Significant redemptions reduced the Trust Account funds by approximately $7.9 million, leaving about $8.2 million in the Trust Account as of June 30, 2026, which may affect the ability to satisfy closing conditions and reduce liquidation value if the combination is not consummated [S2].
• GNQ Insilico Inc. is an AI-driven drug discovery and precision medicine company that entered a joint marketing agreement with a Fortune 100 technology company in March 2026 to advance AI-powered healthcare solutions [N1].
• The company’s common stock and rights are listed on the Nasdaq Stock Market [S1].
• The company is classified as an emerging growth company under SEC rules [S1].
• The company’s management and directors may have conflicts of interest due to founder shares acquired at low cost and other fiduciary obligations [S1].
• The company’s operating segment is singular, with the Chief Financial Officer as the chief operating decision maker, focusing on managing general and administrative expenses and investment income from the Trust Account [S1].